Drug intelligence / Profile preview

EMRANK-016

Development stage: Preclinical
Lead developer: MindRank
Modality: Small Molecules

Overview

EMRANK-016 is a small molecule allosteric inhibitor developed by MindRank as part of its "Design as a Service" (DaaS) platform. The drug is designed to target an undisclosed oncology-related protein via an allosteric binding site. According to MindRank's pipeline, the Preclinical Candidate (PCC) for this program has been delivered, and the candidate is currently in the IND-enabling stage of development. The specific molecular target and the partner company for this co-development project remain undisclosed.

Beyond the preview

Go deeper on EMRANK-016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMRANK-016.

Explore the full profile